AMLo Biosciences’ Post

Karoline Dempsey, MPAS, PA-C Board-Certified Physician Assistant and Diplomate of Dermatology has provided her thoughts on #AMBLor in clinical practice, ahead of the Society of Dermatology Physician Associates #derm_pa Conference in Las Vegas later this week. PA Dempsey sees around 30 patients every day and knows that having as much information about a #melanoma at diagnosis is critical for successful outcomes. AMBLor is the prognostic test that identifies the presence or absence of two biomarker proteins. With at least one protein present, patients are less likely to have progressive melanoma. “AMBLor offers more reassurance that we can give to the patients,” PA Dempsey says. “It is nice to say the analysis was done on their particular melanoma, so it gives me a more personalised result to share.” “Everyone worries because melanoma can be so aggressive. I always feel very reassured when I can say, ‘Hey, I have some good news for you.’” She added. Even when the test results are not what was hoped for, the results are passed to the oncologist to support a more informed treatment plan at this early stage of melanoma. For US residents, access the full piece here: https://bit.ly/3O2oO8Z #dermPAsforDermPAs #dermatology #dermconference #skincancer #oncology #dermatopathology #histopathology #biomarkers

Just a reminder that Professor Phil Sloan and Dr Akhtar Husain, our leading pathology experts, are in the US attending the American Society of Dermatology Annual Meeting 7-10 November #ASDP24. They would be happy to meet and discuss #AMBLor, our biomarker prognostic that accurately identifies early-stage melanomas at low risk of progression. Find out more about how using this test can personalise melanoma management through effective use of further diagnostic procedures and follow-ups, and help ease patient anxiety. Please message Alex Pogorzelski at inquiries@usa.amlo-biosciences.com to arrange a time to chat. Professor Sloan and Dr Husain are also presenting new research on the use of AMBLor technology in #melanoma in situ, #atypicallesions and #spitznaevi, which we hope will lead to further improvements for clinicians to better manage their patients. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. #AMBLor has received its UKCA mark in the UK. #dermatology #histopathology #oncology #skincancer #biomarkers #cancerresreach #dermatopathology #PathologyMatters #PathologyAwareness

Excited to share that I co-authored a poster being presented at the EADV Congress 2024 here in Amsterdam, showcasing phase 3 clinical trial results for secukinumab in treating hidradenitis suppurativa. The data show significant clinical improvement independently of the lesion type at baseline. However, the highest clinical responses were seen for patients with inflammatory nodules only at baseline, highlighting secukinumab’s broad efficacy across different lesion types but reinforcing the need to treat early on disease course. A promising step forward in addressing this challenging condition! #EADV2024 European Academy of Dermatology and Venereology #HidradenitisSuppurativa #ClinicalTrials #Dermatology #immunology

🔍 New study reveals that in the overlap between psoriasis and atopic dermatitis, psoriasis has the dominant molecular features! 🧬 Treat overlap phenotype with psoriasis-focused strategies for better outcomes. 🌟 https://okt.to/7VDIXk #Psoriasis #AtopicDermatitis #SkinHealth #DermatologyResearch #Dermatology

Breaking New Ground in Onco-Dermatology Excited to share our latest publication in the Journal of Drugs in Dermatology (JDD): "USCOM IV Algorithm for the Prevention and Management of Targeted Therapy-Related Cutaneous Adverse Events." This multidisciplinary-guided algorithm provides practical solutions for managing skin-related side effects of targeted cancer therapies. By addressing issues like rash, pruritus, hyperpigmentation, and hand-foot skin reactions, it ensures patients can continue their treatment with minimal disruption to their quality of life. A huge thank you to the collaborative efforts of an incredible team of experts working to improve outcomes in both oncology and dermatology.   Jonathan Leventhal, Ana Sofia Acosta Madiedo MD, Anneke Andriessen PhD,  Jennifer N Choi MD, Alice Ho MD MBA, Beth McLellan MD,  Edith Mitchell MD and  Mario Lacouture, M.D. FAAD 📖 Check out the full article below https://lnkd.in/eUH9uMCx #OncoDermatology #JDDPublication #TargetedTherapies #CancerCare #DermatologyResearch

This recent publication in JAMA Dermatology showed that #melanoma incidence in US veterans was almost four times that of non-veterans , attributed to being outdoors on a workday, and not frequently using sunscreen, staying in the shade, or wearing long sleeve shirts outdoors. Veteran status was associated with a 44% to 45% increased risk of severe sunburn.  https://bit.ly/4ev7nta The study calls for public health measures to mitigate risk and early detection of dermatologic conditions in veterans. Our biomarker prognostic #AMBLor could be used in this population to accurately identify the subset of early-stage melanoma patients who are at low risk of their disease progressing. The simple AMBLor test can be performed on the initial skin sample taken at diagnosis. Understanding the prognosis of a melanoma diagnosis can help physicians direct appropriate procedures and follow-up. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. #dermatology #dermatopathology #histopathology #oncology #cancerresearch #biomarkers  

Melanoma skin cancer ranks as the 𝟏𝟕𝐭𝐡 most prevalent cancer worldwide, according to the World Cancer Research Fund International. Notably, the American Academy of Dermatology anticipates over 𝟐𝟎𝟎,𝟑𝟒𝟎 new cases of melanoma in 2024 alone. May holds particular significance as 𝐒𝐤𝐢𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡, dedicated to educating the public about the risks associated with skin cancer and highlighting the critical importance of early detection. This month-long campaign aims to promote regular skin examinations, and encourage the adoption of protective measures such as sunscreen and protective clothing. In this regard, biopsy devices play an indispensable role in the early detection and diagnosis of skin cancer. These specialized tools enable dermatologists and oncologists to obtain tissue samples for histopathological examination, a crucial step in achieving an accurate diagnosis. The improved accuracy and efficiency of modern biopsy devices, coupled with their minimally invasive nature, have solidified their position in dermatological practices, offering precise and rapid results. For a comprehensive understanding of the pivotal role played by biopsy devices in skin cancer detection, refer to our market report on biopsy devices: https://lnkd.in/gDuiMJr . . . Ad-Tech Medical Instrument Corporation BD Cardinal Health Planmeca #skincancerawareness #biopsydevice #healthcare #medicaldevices #melanoma #skincancer #dermatology #marketinsights #tritonmarketresearch

🚀 When Expertise is Rare: A Dermatology Case That Demands Attention! Meet my recent patient battling Mycosis Fungoides, a rare cutaneous lymphoma. Her story isn’t just about persistence; it’s a stark reminder of the challenges in finding specialized expertise for rare diseases. Here’s why her journey matters: 🔍 The Challenge 15+ years of unresolved symptoms: severe xerosis, desquamation, and failed treatments. Biopsy-confirmed mycosis fungoides (T?N0M0B0) with reactive lymph nodes, but no systemic spread. A prior 15-day PUVA therapy (age 15) was insufficient. The biggest hurdle? Finding clinicians with deep expertise in staging rare cutaneous lymphomas. Without specialists, clarifying the ambiguous “T?” stage and tailoring treatment becomes a monumental task. 🌟 The Strategy A multidisciplinary team (dermatology + hematology + oncology) stepped up, but not without struggles: 1️⃣ Revisiting PUVA: Optimizing dose/frequency + combining with topical therapies. 2️⃣ Seeking Rare Expertise: Collaborating globally to consult specialists familiar with mycosis fungoides staging nuances. 3️⃣ Vigilant Monitoring: Ruling out Sézary syndrome, bone marrow involvement, and long-term UV risks. 💡 Why This Matters Rarity demands specialization: Cases like her highlight the gap in accessible expertise for rare diseases. Teamwork bridges gaps: When local experts are scarce, multidisciplinary collaboration and external consults become lifelines. Chronic diseases test systems: Even “simple” staging uncertainties (like “T?”) can stall care without the right knowledge. 🤔 Food for Thought How do YOU navigate finding experts for rare conditions in your practice? Should hospitals invest in “rare disease networks” to bridge these gaps? Can telemedicine democratize access to specialized knowledge? #RareDiseases #Dermatology #MedicalExpertise #HealthcareCollaboration #PatientAdvocacy #mycosisfungoides

We were interested to read an article published in Dermatology and Therapy emphasising the need to find disease-specific #biomarkers for #skincancer. The review focuses on molecular and histologic biomarkers that are relevant to patient management, including prevention/risk assessments, tumour diagnosis, and therapy selection. https://bit.ly/3WgvtQI Here at AMLo Biosciences we have developed our biomarker technology, #AMBLor, that accurately identifies early-stage #melanomas at low-risk of progression. This prognostic information can risk-stratify melanomas helping clinical decision makers with personalised disease management and follow-up. Find out more: www.amlo-biosciences.com   AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. The AMBRA1 and loricrin test is available in the UK as a UKAS accredited LDT. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers 

Scientists at the National Institutes of Health (#nih) have #discovered that the #presence of a #benign #nail #abnormality may lead to the #diagnosis of a #rare #inherited #disorder that increases the #risk of developing #cancerous #tumors of the #skin, #eyes, #kidneys and the #tissue that lines the #chest and #abdomen (e.g., the #mesothelium). The #condition, known as BAP1 #tumor #predisposition #syndrome, is caused by #mutations in the BAP1 #gene, which normally acts as a tumor #suppressor, among other #functions. The #findings are published in JAMA Dermatology and will be presented today at the Society for Investigative Dermatology Annual Meeting in Dallas. https://lnkd.in/eumSu8cX